GLP-1 medications have transformed medical weight management. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are both highly effective once-weekly injectable medications — but they work differently and produce different results. Dr. Richard Nguyen at Lifetime Surgical prescribes both medications and guides patients in San Jose and Los Gatos through the decision.
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. Originally developed for type 2 diabetes as Ozempic, it was later FDA-approved for chronic weight management at a higher dose as Wegovy. It works by reducing appetite, slowing gastric emptying, and improving insulin sensitivity.
Tirzepatide is a dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonist — the first of its kind. The added GIP activity enhances weight loss beyond what GLP-1 alone produces. Mounjaro is the diabetes formulation; Zepbound is for chronic weight management.
Tirzepatide has demonstrated superior weight loss. In the SURMOUNT-1 trial, patients lost up to 22.5% of body weight at the highest dose — significantly more than semaglutide's ~15% in the STEP trials. For patients prioritizing maximum weight loss, tirzepatide currently leads.
Both medications share similar gastrointestinal side effects: nausea, vomiting, diarrhea, and constipation, particularly during the dose escalation phase. These typically improve with time. Most patients tolerate both medications well when doses are escalated gradually.
Semaglutide has robust cardiovascular outcome data from the SELECT trial, demonstrating a 20% reduction in major cardiovascular events. Tirzepatide's SURMOUNT-MMO trial is ongoing, with preliminary data suggesting comparable or superior cardiovascular benefits.
Both medications retail at $1,000–$1,500/month without insurance. Coverage varies widely. Manufacturer savings programs can significantly reduce out-of-pocket costs. Dr. Nguyen's team helps navigate insurance authorization and prior approvals.
Both medications significantly improve blood glucose control and HbA1c. Tirzepatide often produces more potent HbA1c reductions due to its dual GLP-1/GIP mechanism, making it particularly beneficial for patients with type 2 diabetes or insulin resistance.
These medications work best as part of a comprehensive program that includes dietary guidance, behavioral support, and regular monitoring. Dr. Nguyen evaluates each patient's metabolic health, goals, and medical history before prescribing either medication.
Contact Lifetime Surgical in San Jose or Los Gatos to schedule a medical weight loss consultation.
Wondering which surgical procedure might be right for your condition? We're here to help you understand your treatment options and develop a personalized surgical plan. Contact our office today to schedule a consultation.
Your path to improved health may be more achievable than you think—with advanced surgical techniques leading to faster recovery, reduced complications, and a significantly enhanced quality of life.
.avif)
